CA2923053C - Methods for treating conditions associated with masp-2 dependent complement activation - Google Patents

Methods for treating conditions associated with masp-2 dependent complement activation Download PDF

Info

Publication number
CA2923053C
CA2923053C CA2923053A CA2923053A CA2923053C CA 2923053 C CA2923053 C CA 2923053C CA 2923053 A CA2923053 A CA 2923053A CA 2923053 A CA2923053 A CA 2923053A CA 2923053 C CA2923053 C CA 2923053C
Authority
CA
Canada
Prior art keywords
masp
complement
activation
glomerulonephritis
inhibitory agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2923053A
Other languages
English (en)
French (fr)
Other versions
CA2923053A1 (en
Inventor
Hans-Wilheim Schwaebel
Cordula Margaret Stover
Clark E. Tedford
James B. Parent
Teizo Fujita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leicester
Omeros Corp
Original Assignee
University of Leicester
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leicester, Omeros Medical Systems Inc filed Critical University of Leicester
Publication of CA2923053A1 publication Critical patent/CA2923053A1/en
Application granted granted Critical
Publication of CA2923053C publication Critical patent/CA2923053C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biodiversity & Conservation Biology (AREA)
CA2923053A 2006-04-03 2007-03-27 Methods for treating conditions associated with masp-2 dependent complement activation Active CA2923053C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US78887606P 2006-04-03 2006-04-03
US60/788,876 2006-04-03
US11/645,359 US7919094B2 (en) 2004-06-10 2006-12-22 Methods for treating conditions associated with MASP-2 dependent complement activation
US11/645,359 2006-12-22
CA2648188A CA2648188C (en) 2006-04-03 2007-03-27 Methods for treating conditions associated with masp-2 dependent complement activation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2648188A Division CA2648188C (en) 2006-04-03 2007-03-27 Methods for treating conditions associated with masp-2 dependent complement activation

Publications (2)

Publication Number Publication Date
CA2923053A1 CA2923053A1 (en) 2007-10-18
CA2923053C true CA2923053C (en) 2020-10-27

Family

ID=38581755

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2923053A Active CA2923053C (en) 2006-04-03 2007-03-27 Methods for treating conditions associated with masp-2 dependent complement activation
CA2648188A Active CA2648188C (en) 2006-04-03 2007-03-27 Methods for treating conditions associated with masp-2 dependent complement activation

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2648188A Active CA2648188C (en) 2006-04-03 2007-03-27 Methods for treating conditions associated with masp-2 dependent complement activation

Country Status (19)

Country Link
US (5) US7919094B2 (https=)
EP (2) EP2007425B1 (https=)
JP (1) JP5567328B2 (https=)
KR (1) KR101522258B1 (https=)
CN (2) CN101460195B (https=)
BR (1) BRPI0709900A2 (https=)
CA (2) CA2923053C (https=)
CY (1) CY1125274T1 (https=)
DK (2) DK2007425T3 (https=)
ES (2) ES2781687T3 (https=)
HU (2) HUE048745T2 (https=)
LT (2) LT2007425T (https=)
MX (2) MX2008011704A (https=)
NZ (1) NZ597489A (https=)
PL (2) PL3067067T3 (https=)
PT (2) PT3067067T (https=)
RU (1) RU2484097C2 (https=)
SI (1) SI3067067T1 (https=)
WO (1) WO2007117996A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2852828C1 (ru) * 2025-05-16 2025-12-16 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева" Министерства здравоохранения Российской Федерации Способ прогнозирования задержки роста плода с врожденным пороком сердца

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
EP2386316B1 (en) 2004-06-10 2018-02-28 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
EP2357254A1 (en) 2005-02-14 2011-08-17 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
US20080269730A1 (en) 2005-04-14 2008-10-30 Dotson Robert S Ophthalmic Phototherapy Device and Associated Treatment Method
US20130079759A1 (en) 2005-04-14 2013-03-28 Robert S. Dotson Ophthalmic Phototherapy Device and Associated Treatment Method
US8524453B2 (en) * 2006-02-10 2013-09-03 The Brigham And Woman's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
KR101584468B1 (ko) * 2006-03-08 2016-01-13 아케믹스 엘엘씨 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제
WO2007149567A2 (en) 2006-06-21 2007-12-27 Musc Foundation For Research Development Targeting complement factor h for treatment of diseases
EP2278987A4 (en) * 2008-03-28 2012-08-22 Apellis Ag MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
WO2010039690A1 (en) * 2008-09-30 2010-04-08 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
LT2894165T (lt) 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
HUP0900319A2 (en) * 2009-05-25 2011-01-28 Eotvos Lorand Tudomanyegyetem New peptides, method of producing therof and use thereof
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
CN102781471B (zh) * 2009-10-16 2016-10-12 奥默罗斯公司 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法
MX2012005151A (es) 2009-11-05 2012-08-23 Federico Ii University Of Naples Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
CN102844053B (zh) 2009-11-25 2015-08-05 洛马林达大学医学中心 基于壳聚糖的止血织物
CA2791841C (en) 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
EP2824111B1 (en) 2010-04-30 2017-03-22 Alexion Pharmaceuticals, Inc. Anti-C5A Antibodies and Methods for Using the Antibodies
WO2011143637A1 (en) 2010-05-14 2011-11-17 The Regents Of The University Of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
US9815890B2 (en) 2010-06-22 2017-11-14 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the C3d fragment of complement component 3
HUP1000366A2 (en) * 2010-07-13 2012-03-28 Mta Enzimologiai Intezet Novel proteins, their production process and use tereof
US9295713B2 (en) * 2010-09-15 2016-03-29 Celldex Therapeutics, Inc. Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
AU2015271989B2 (en) * 2011-04-08 2017-09-21 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR101870915B1 (ko) * 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
AU2013201626B2 (en) * 2011-04-08 2016-02-11 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2013201779B2 (en) * 2011-05-04 2016-01-07 Omeros Corporation Compositions for inhibiting MASP-2 dependent complement activation
EP2704743B1 (en) 2011-05-04 2020-03-11 Omeros Corporation Compositions for inhibiting masp-2 dependent complement acitivation
CN103796667A (zh) 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
AU2012278326A1 (en) * 2011-06-28 2014-01-16 Kobenhavns Universitet Therapeutic targeting of Ficolin-3
US10350277B2 (en) 2011-09-07 2019-07-16 Icahn School Of Medicine At Mount Sinai Ceramidase and cell differentiation
WO2013106572A1 (en) 2012-01-11 2013-07-18 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Bispecific antibody fragments for neurological disease proteins and methods of use
US20150297674A1 (en) * 2012-03-12 2015-10-22 Loma Linda University Medical Center Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or disease
WO2013180834A2 (en) * 2012-04-06 2013-12-05 Omeros Corporation Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria
PL2854910T3 (pl) 2012-06-01 2020-07-27 Icahn School Of Medicine At Mount Sinai Poziomy ceramidu w leczeniu i zapobieganiu infekcjom
KR102339315B1 (ko) 2012-06-18 2021-12-15 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
CA2905449C (en) 2013-03-14 2024-09-10 Icahn School Of Medicine At Mount Sinai THERAPEUTIC COMPOSITIONS OF ACID CERAMIDASE AND THEIR PROCESSES OF MANUFACTURE AND USE
CA3216595A1 (en) 2013-03-14 2014-10-02 Kevin Fitzgerald Complement component c5 irna compositions and methods of use thereof
ES2964340T3 (es) 2013-03-15 2024-04-05 Omeros Corp Métodos para generar anticuerpos portadores de péptidos bioactivos y composiciones que comprenden los mismos
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
ES2768648T3 (es) 2013-03-29 2020-06-23 Alexion Pharma Inc Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento
RU2549468C2 (ru) * 2013-08-09 2015-04-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН") Способ определения стабилизации с3-конвертазы классического пути активации комплемента человека
SMT202000659T1 (it) 2013-10-17 2021-01-05 Omeros Corp Metodi per il trattamento delle condizioni associate all'attivazione del complemento dipendente dalla masp-2
SG10201804960RA (en) 2013-12-12 2018-07-30 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US20150353623A1 (en) * 2014-04-03 2015-12-10 Loma Linda University Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or diseases
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
CN107072821B (zh) 2014-09-09 2022-07-01 卢米希拉公司 用于损伤或患病组织的非侵入性治疗的多波长光疗装置、系统和方法
EP3191591A1 (en) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
MX2017004742A (es) 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
WO2016081314A1 (en) 2014-11-17 2016-05-26 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to a complement inhibitor
WO2016164358A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
EP4365291A3 (en) 2015-06-12 2024-08-14 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
CA3001661C (en) * 2015-10-14 2025-05-06 Massachusetts Eye And Ear Infirmary HIGH-DOSE STATINS FOR AGE-RELATED MACULAR DEGENERATION
CN108472347B (zh) 2015-11-09 2023-09-05 奥默罗斯公司 用于治疗与masp-2依赖性补体活化相关的病况的方法
US10736960B2 (en) * 2016-01-05 2020-08-11 Omeros Corporation Methods for inhibiting fibrosis in a subject in need thereof
WO2017173290A1 (en) 2016-03-31 2017-10-05 Omeros Corporation Methods for inhibiting angiogenesis in a subject in need thereof
KR20190005944A (ko) * 2016-05-09 2019-01-16 애넥슨, 인코포레이티드 척수성 근위축 치료용 조성물 및 방법
JP2019517473A (ja) 2016-05-27 2019-06-24 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 難治性全身型重症筋無力症の処置のための方法
EP3469083A1 (en) 2016-06-10 2019-04-17 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
CN109475626A (zh) * 2016-07-14 2019-03-15 儿童医院医疗中心 治疗纤维化的方法
JOP20170154B1 (ar) 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
HUE073475T2 (hu) 2016-10-12 2026-01-28 Bioverativ Usa Inc C1s elleni antitestek és alkalmazási eljárásaik
IL265981B2 (en) * 2016-10-13 2025-05-01 Univ Leicester Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
SI3658184T1 (sl) 2017-07-27 2024-01-31 Alexion Pharmaceuticals, Inc., Formulacije z visoko koncentracijo protiteles proti-C5
TWI818919B (zh) 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
CN107288615B (zh) * 2017-08-17 2023-05-16 西南石油大学 一种激光固相沉积仪器及其测试方法
CA3080187A1 (en) 2017-10-26 2019-05-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
AU2018360697A1 (en) 2017-11-01 2020-05-14 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
CN112867706B (zh) 2018-05-29 2024-11-15 奥默罗斯公司 Masp-2抑制剂和使用方法
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
US12404320B2 (en) 2018-05-31 2025-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
JP7577542B2 (ja) 2018-06-04 2024-11-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
WO2020006266A1 (en) 2018-06-28 2020-01-02 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
CN112996561A (zh) 2018-10-30 2021-06-18 亚力兄制药公司 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用
CA3139209A1 (en) 2019-05-07 2020-11-12 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
KR102180733B1 (ko) * 2019-07-12 2020-11-19 건국대학교 산학협력단 탈지우유를 유효성분으로 포함하는 줄기세포 분리용 조성물
RU2732765C1 (ru) * 2019-07-25 2020-09-22 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ коррекции реперфузионно-ишемического повреждения при резекции почки по поводу локализованного рака в условиях тепловой ишемии
EP4054634A1 (en) 2019-11-08 2022-09-14 Alexion Pharmaceuticals, Inc. High concentration anti-c5 antibody formulations
WO2021108447A1 (en) * 2019-11-26 2021-06-03 Omeros Corporation Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant
EP4069676A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
BR112022010881A2 (pt) 2019-12-04 2022-08-23 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado a serina protease-2 associada à lectina de ligação ao manan
IL293550A (en) 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
JP7699389B2 (ja) 2019-12-04 2025-06-27 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
WO2021163980A1 (zh) * 2020-02-21 2021-08-26 中国人民解放军军事科学院军事医学研究院 靶向masp-2、n蛋白或其结合的物质预防和/或治疗冠状病毒感染
TWI834025B (zh) 2020-03-06 2024-03-01 美商奥默羅斯公司 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法
MX2022013606A (es) 2020-04-30 2023-01-16 Alnylam Pharmaceuticals Inc Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
CN111893090B (zh) * 2020-08-17 2023-10-27 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种动脉粥样硬化防治药物筛选细胞模型及其构建和应用
EP4240750A1 (en) 2020-11-04 2023-09-13 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
EP4011904A1 (en) 2020-12-14 2022-06-15 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022103638A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Cannabinoids in the treatment of autism spectrum disorder
CN114634575B (zh) * 2020-12-16 2025-04-11 康诺亚生物医药科技（成都）有限公司 一种补体抑制剂的开发和应用
EP4274896A1 (en) 2021-01-05 2023-11-15 Alnylam Pharmaceuticals, Inc. Complement component 9 (c9) irna compositions and methods of use thereof
TW202305010A (zh) * 2021-04-25 2023-02-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｍａｓｐ２抗體、其抗原結合片段及醫藥用途
AU2022279806A1 (en) * 2021-05-26 2023-11-30 Kao Corporation Agent for preventing or ameliorating pruritus
EP4353749A4 (en) * 2021-06-08 2025-07-16 Shanghai Jemincare Pharmaceuticals Co Ltd ANTI-MASP-2 ANTIBODY AND ITS USE
JP2024535850A (ja) 2021-09-17 2024-10-02 アルナイラム ファーマシューティカルズ， インコーポレイテッド 補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
TW202333749A (zh) 2021-10-29 2023-09-01 美商艾拉倫製藥股份有限公司 補體因子ｂ（ｃｆｂ）ｉｒｎａ組成物及其使用方法
WO2023108028A2 (en) * 2021-12-10 2023-06-15 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
JP2025541737A (ja) 2022-11-30 2025-12-23 オメロス コーポレーション Ｍａｓｐ－２阻害物質としての縮合ピリミジン
EP4643878A2 (en) * 2022-12-29 2025-11-05 Suzhou Transcenta Therapeutics Co., Ltd. Pharmaceutical preparation comprising therapeutic antibody and use thereof
US20250122225A1 (en) 2023-10-06 2025-04-17 Omeros Corporation Masp-2 inhibitors and methods of use
WO2025092910A1 (zh) * 2023-10-31 2025-05-08 石药集团中奇制药技术（石家庄）有限公司 一种抑制补体MASP2基因表达的dsRNA分子及其应用
WO2025199107A1 (en) 2024-03-19 2025-09-25 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US552157A (en) * 1895-12-31 Sterilizer for bandages
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) * 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) * 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) * 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (ja) * 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
ATE115999T1 (de) 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) * 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
JP3218637B2 (ja) * 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) * 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
AU4467396A (en) 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6297024B1 (en) * 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
JP2002532079A (ja) 1998-12-15 2002-10-02 ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド 補体活性化に関連するレクチン補体経路を調節するための方法および産物
US6235494B1 (en) * 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
EP1181038B1 (en) * 1999-05-14 2004-04-14 Steffen Thiel Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals
RU2271825C2 (ru) 1999-07-21 2006-03-20 Омерос Корпорейшн Растворы и способы ингибирования боли, воспаления и разрушения хряща
JP2003507338A (ja) 1999-08-13 2003-02-25 ザ ブリグハム アンド ウイメンズ ホスピタル インコーポレイテッド レクチン補体経路（ｌｃｐ）のインヒビターおよびその使用
US6794132B2 (en) * 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US20030186419A1 (en) * 1999-12-02 2003-10-02 Jensenius Jens Christian Masp-3, a complement-fixing enzyme, and uses for it
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
AU2001261103B2 (en) 2000-04-29 2007-08-23 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
NZ523900A (en) 2000-07-13 2004-02-27 Jens Christian Jensenius Isolation and characterisation of a mannan-binding lectin (MBL) associated serine protease (MASP-2) and uses thereof to treat infections
US20020094332A1 (en) 2001-01-18 2002-07-18 Alexion Pharmaceuticals Method of prophylaxis against large myocardial infractions
CA2454562A1 (en) 2001-07-26 2003-02-06 Alexion Pharmaceuticals, Inc. Method of improving cognitive function
CA2473786A1 (en) 2002-01-22 2003-07-31 Alexion Pharmaceuticals, Inc. Method of prophylaxis against large myocardial infarctions
EP1496835A4 (en) 2002-02-01 2006-10-18 Omeros Corp COMPOSITIONS AND METHODS FOR THE SYSTEMIC SUPPRESSION OF CARTON DECOMPOSITION
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US6644119B1 (en) * 2002-06-28 2003-11-11 The Regents Of The University Of California Noninvasive characterization of a flowing multiphase fluid using ultrasonic interferometry
AU2003249317B2 (en) 2002-07-19 2007-08-02 Institute Of Materials Research And Engineering Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
PT1534313E (pt) 2002-07-30 2013-01-25 Omeros Corp Soluções e método de irrigação oftalmológica
WO2004022096A1 (en) 2002-09-06 2004-03-18 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
EP1570075A2 (en) 2002-12-03 2005-09-07 Aarhus Universitet Method for determing predisposition to manifestation of immune system related diseases
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
AU2004216176B2 (en) 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
EP1609804B1 (en) * 2003-03-17 2012-06-13 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Construct comprising recognition domain of antibody against von willebrand factor-specific cleaving enzyme
DE10324862A1 (de) * 2003-05-05 2005-03-03 Dirr, Josef, Dipl.-Ing. (FH) Verfahren zur Verschlüsselung digitalisierter Information
EP1625166B1 (en) 2003-05-12 2015-04-08 Helion Biotech ApS Antibodies to masp-2
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005024013A1 (en) 2003-09-05 2005-03-17 Natimmune A/S Masp-2 crystal structure and uses thereof
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
EP2386316B1 (en) * 2004-06-10 2018-02-28 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2005123776A1 (en) * 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with lectin-dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2005262070B2 (en) * 2004-07-09 2011-01-27 Ferrosan Medical Devices A/S Haemostatic composition comprising hyaluronic acid
WO2006133955A1 (en) * 2005-06-17 2006-12-21 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
NZ597259A (en) * 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2852828C1 (ru) * 2025-05-16 2025-12-16 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева" Министерства здравоохранения Российской Федерации Способ прогнозирования задержки роста плода с врожденным пороком сердца

Also Published As

Publication number Publication date
CY1125274T1 (el) 2023-03-24
EP3067067A1 (en) 2016-09-14
LT3067067T (lt) 2020-05-25
DK3067067T3 (en) 2020-04-14
WO2007117996A2 (en) 2007-10-18
US7919094B2 (en) 2011-04-05
CN101460195A (zh) 2009-06-17
ES2589315T3 (es) 2016-11-11
BRPI0709900A2 (pt) 2011-07-26
EP3067067B1 (en) 2020-01-08
SI3067067T1 (sl) 2020-10-30
WO2007117996A3 (en) 2007-12-21
AU2007234982A1 (en) 2007-10-18
EP2007425A4 (en) 2010-07-07
PL3067067T3 (pl) 2020-08-24
NZ597489A (en) 2013-08-30
DK2007425T3 (en) 2016-08-22
MX366119B (es) 2019-06-27
EP2007425A2 (en) 2008-12-31
EP2007425B1 (en) 2016-05-11
MX2008011704A (es) 2009-01-19
US20100074899A1 (en) 2010-03-25
HUE048745T2 (hu) 2020-09-28
CA2648188C (en) 2016-05-17
RU2484097C2 (ru) 2013-06-10
CA2923053A1 (en) 2007-10-18
KR101522258B1 (ko) 2015-05-21
CN103705921B (zh) 2018-03-20
CA2648188A1 (en) 2007-10-18
CN103705921A (zh) 2014-04-09
LT2007425T (lt) 2016-09-26
US20170233493A1 (en) 2017-08-17
HUE028834T2 (en) 2017-01-30
HK1121961A1 (zh) 2009-05-08
JP2009532493A (ja) 2009-09-10
KR20080112359A (ko) 2008-12-24
US20200190215A1 (en) 2020-06-18
US20110020337A1 (en) 2011-01-27
JP5567328B2 (ja) 2014-08-06
RU2008143559A (ru) 2010-05-10
PL2007425T3 (pl) 2017-01-31
CN101460195B (zh) 2013-11-20
PT2007425T (pt) 2016-08-17
PT3067067T (pt) 2020-04-20
ES2781687T3 (es) 2020-09-04
US20070172483A1 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
US20240228665A1 (en) Methods for treating conditions associated with masp-2 dependent complement activation
US20200190215A1 (en) Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
AU2010306581B2 (en) Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
US20170166660A1 (en) Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
WO2005123128A2 (en) Methods for treating conditions associated with masp-2 dependent complement activation
AU2020203750A1 (en) Methods for treating conditions associated with MASP-2-dependent complement activation
US20230391889A1 (en) Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
AU2013201443B2 (en) Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
US20240076408A1 (en) Methods for treating conditions associated with masp-2 dependent complement activation
AU2007234982B2 (en) Methods for treating conditions associated with MASP-2 dependent complement activation
HK1228289B (en) Methods for treating conditions associated with masp-2 dependent complement activation
HK1228289A1 (en) Methods for treating conditions associated with masp-2 dependent complement activation
HK1121961B (en) Methods for treating conditions associated with masp-2 dependent complement activation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160825

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250321